Welcome!

News Feed Item

AbbVie Announces Availability of New Advanced Parkinson's Treatment in Canada

DUODOPA improves quality of life for those with advanced stages of disease

MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA® (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's – a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers.

DUODOPA is approved in Canada for the management of advanced Parkinson's disease in adults with severe, disabling motor fluctuations and hyper-/dyskinesia (involuntary movements) not satisfactorily controlled by combinations of available oral medicinal products for Parkinson's disease.

"A major problem that emerges over time in people with Parkinson's disease is fluctuations in their ability to move due to unreliable absorption of oral medications. This leads to inconsistent delivery of the chemical dopamine which controls movement to the brain resulting in unpredictable motor function," said Dr. Anthony Lang of the Movement Disorder Centre at Toronto Western Hospital, University Health Network, which is one of four centers of excellence in Canada to treat advanced Parkinson's patients with this new treatment. "DUODOPA is a treatment option that enables patients to regain control over their movements and balance which in turn drastically improves their quality of life."

Parkinson's disease, which involves significant loss of limb and balance control, is most commonly diagnosed at 50-60 years of age – although diagnosis can occur at a much younger age. The standard treatment for Parkinson's disease begins with oral therapies, including levodopa, which usually work well during the first years. As the disease progresses, oral therapies no longer provide satisfactory control over severe motor fluctuations and dyskinesia. Now with DUODOPA there is a new option.

"I am a writer and I could not write. I would have very painful tremors in my right hand and rigidity on my entire left side," said Doug Curtis, a playwright who has been living with Parkinson's disease for 10 years. He is one of the first Parkinson's patients in North America to receive DUODOPA.  "Parkinson's took away my ability to express myself. But now I can write again. The tempo of my life has returned.  I now have the confidence to take on Parkinson's head on."

"My husband was progressively getting worse as he moved into the advanced stages of the disease. Simple daily tasks became a challenge and he became dependent on me," said Heather Moore, Doug's wife and caregiver. "Today, I see Doug's condition improving and because of this progress my family has regained a sense of normalcy in our lives."

About Parkinson's Disease (PD)
PD is a progressive neurological disease that affects approximately 6.3 million people, making it the second most common degenerative neurological disorder worldwide1,2.

The severity of PD and how it impacts an individual varies from person to person. The symptoms are predominantly characterized by problems with body movements, called motor symptoms3. These symptoms include tremor, or shaking (often in the hand, arm or leg); rigidity, or stiffness in muscles; slowness of movement, and poor balance and instability3,4. As the disease progresses, these symptoms can worsen to the point where a person becomes dependent on others to perform even basic activities, such as help getting out of a chair and turning over in bed3,5.

Currently there is no cure for PD and symptoms may gradually continue to worsen in the years following diagnosis6. The goal of treatment for PD is to manage motor symptoms, which reduces tremor, rigidity and slowness of movement1.

About DUODOPA

  • DUODOPA® is indicated for treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyper-/dyskinesia when available combinations of PD medicinal products have not given satisfactory results7.
  • DUODOPA® provides an effective treatment for people with PD enabling more "ON" time in comparison to oral levodopa7.
  • DUODOPA® was approved in recognition of a high unmet need for effective therapies and no satisfactory alternatives8.
  • DUODOPA® is contraindicated in patients with narrow-angle glaucoma, severe liver and renal insufficiency, severe heart failure, severe cardiac arrhythmia, suspicious, undiagnosed skin lesions or a history of melanoma, acute stroke and in patients taking non-selective MAO inhibitors and selective MAO type A inhibitors7.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com and www.abbvie.ca. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

________________________________________
1
Mobin A. A comparative analysis of how Michael J. Fox and Muhammad Ali changed the world's views on Parkinson's disease. J Parkinsonism Restless Legs Syndrome 2011;1:1–4.
2 de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525–35.
3 Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–376.
4 Clarke CE. Parkinson's disease. BMJ 2007;335:441–445.
5 ICD9 Data.com. Parkinson's disease 332. Available at: http://www.icd9data.com/2013/Volume1/320-389/330-337/332/default.htm (Last accessed December 2013).
6 Denyer R, Douglas MR. Gene therapy for Parkinson's disease. Parkinsons Dis 2012;2012:757305.
7 AbbVie Limited. Summary of product characteristics: Duodopa intestinal gel, October 2013. Available at: http://www.medicines.org.uk/emc/medicine/20786/SPC/Duodopa+intestinal+gel/ (Last accessed December 2013).
8 European Medicines Agency. Public summary of opinion on orphan designation: levodopa/carbidopa (gastroenteral use) for the treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations and not responding to oral treatment. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006499.pdf (Last accessed December 2013).

SOURCE AbbVie

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTred processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Did you know that you can develop for mainframes in Java? Or that the testing and deployment can be automated across mobile to mainframe? In his session at @DevOpsSummit at 20th Cloud Expo, Vaughn Marshall, Sr. Principal Product Owner at CA Technologies, will discuss and demo how increasingly teams are developing with agile methodologies using modern development environments and automating testing and deployments, mobile to mainframe.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...